Investor Centre
Welcome to the Actinogen Investor Centre. Here, shareholders and prospective investors can find all the essential information for investors ranging from the current share price to the latest announcements to the Australian Securities Exchange (ASX), which is the source of all material information announced by the company.
For the full suite of investor centre topics in a drop-down menu, simply click on the Investor Centre tab at the top of the page or use the simple menu directly above for a shortcut to the most popular sections.
Please also check out the rest of the website for general information about the company, our clinical trial programs and important information on the Board, the Leadership Team, and our corporate governance policies.
If there is anything else you would like assistance with, please contact our share registrar, Automic, for management of your individual Actinogen shareholding, or the ACW Investor Relations team for questions about the company itself – go to Contact Us page for contact details.
Press Releases
All Actinogen Press Releases2024 Annual General Meeting
Read moreASX Announcements
Corporate Presentations
Latest Summary Corporate Presentation
View Presentation-
15 May 2025
ACW Clinical Trials Science Forum 2025 – The critical importance of preparing for commercialization [1.00 hr]
-
24 Jan 2025
Executive Interview: Edison Group interviews Dr Steven Gourlay (23m39s)
-
12 Jan 2025
Video recording: Actinogen Medical at the Sachs Neuroscience Innovation Forum 2025 (17m: 44s)
-
18 Sep 2024
Webcast Video Recording: ACW $11.1 capital raising
Analyst Reports
-
08 Jul 2025
Edison Investment Research update
Actinogen Medical – XanaMIA study enrols 100th patientThis report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
06 Apr 2025
Bioshares Edition 972:
Actinogen Medical – Progressing its Phase IIb/III Alzheimer’s StudyActinogen Medical Limited (Company) is a Corporate Subscriber to Bioshares which prepared this report. The report solely reflects the views of Bioshares.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Bioshares at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
13 Feb 2025
Edison Investment Research update
Actinogen Medical – XanaMIA Phase IIb/III study marches onThis report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
15 Oct 2024
Edison Investment Research update
Actinogen Medical – A$11.1m capital raise completedThis report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report
Right to Receive Documents
Find out moreFrequently Asked Questions
The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine from Edinburgh University, a company focused on the development of brain penetrant 11β-HSD1 enzyme inhibitors for the treatment of cognitive impairment. The lead drug in development by Corticrine was Xanamem. Corticrine received A$25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 (Xanamem) in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.
Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000
The share registry is managed by Automic Pty Ltd. To login and access your holding information, please go to: https://investor.automic.com.au
Shareholders can check their shareholdings by logging into the Automic investor portal https://investor.automic.com.au
If you have any queries in relation to your shareholding, please contact Automic by telephone on 1300 288 664 (within Australia) or +61 2 9698 5414 (international) or by email at hello@automicgroup.com.au.
All company shares are traded on the Australian Securities Exchange (ASX) and can be bought or sold through a licensed stockbroker. The process of buying or selling shares is explained on the ASX website; please go to
https://www.asx.com.au/products/shares/buying-selling-shares.htm
Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.
All annual reports are available on our website through this link.
Current share prices are available on the ASX website www.asx.com.au and can be searched using the Company’s ASX ticker symbol: ACW. A 20-minute delayed share price graph can also be found in our Investor Centre.
The ASX ticker code for the Company is ASX:ACW
The latest financial reports can be found in our Results Centre.
The Company’s end of financial year is the 30th of June
As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end. Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.
The Company’s auditors are Ernst and Young
K&L Gates
Peter Webse
Email: pwebse@governancecorp.com.au
Our Corporate Governance Statement can be found on our website at: https://actinogen.com.au/investor-centre/#corporate-governance
This section includes downloadable PDFs of our Board and Committee Charters, the Constitution, Anti-Bribery and Corruption Policy, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Policy, Risk Management and Internal Compliance and Control, Securities Trading Policy, and Shareholders Communication Policy.
The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses it against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.
Corporate Governance
Find out moreInvestor Contacts
Actinogen Medical Ltd (ACN 086 778 476) is listed on the Australian Securities Exchange (ASX) with the code ACW.
Retail shareholder queries should be directed to Actinogen Medical’s share registrars, Automic Pty Ltd.
| Address: |
Level 5, 126 Phillip Street GPO Box 5193 |
| Phone: |
+61 1300 288 664 (within Australia) |
| Email: | |
| Web: |
